Special Issue

Heterocyclic Compounds in Medicinal Chemistry: New Advances

Message from the Guest Editors

Heterocyclic systems represent a privileged scaffold in Medicinal Chemistry, as they are present in the majority of organic compounds exhibiting important and diverse biological activities. New biological targets and new emergent diseases are constantly being discovered, and at the same time, heterocyclic-based compounds are found in more than 90% of novel drugs, with new anti-COVID-19 authorized drugs representing a clear example of heterocyclic-based drugs. In this context. heterocyclic chemistry and heterocyclic-based drugs need to be continuously designed and developed. The main goal of this Special Issue is to bring together research from experts in this field, and we are inviting you to contribute to this Special Issue articles, perspectives, and reviews covering all new aspects related to the design, identification and access, molecular characterization, development, and pharmacological evaluation of new active heterocyclic systems. We look forward to your valuable contribution.

Guest Editors

Dr. Giorgio Giorgi

Dr. Gonzalo Recabarren Gajardo

Prof. Dr. Rino Ragno

Deadline for manuscript submissions

closed (25 July 2024)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/189932

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/pharmaceuticals





Pharmaceutica

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals*.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

